- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01476280
Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting
November 17, 2011 updated by: Soo Kyoung Park, Incheon St.Mary's Hospital
A Randomized Double Blind Study to Evaluate Efficacy of Ramosetron and Palonosetron for Prevention of Postoperative Nausea and Vomiting After Gynaecological Laparoscopic Surgery
Ramosetron and palonosetron are more recently developed 5-hydroxytryptamine type 3 receptor antagonists and this randomized double blind study was designed to compare efficacy of ramosetron and palonosetron to prevent postoperative nausea and vomiting.
Investigator hypothesized that palonosetron would have stronger and longer lasting antiemetic effect compared with ramosetron and evaluated the patients for the first 48 hours after surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Incheon, Korea, Republic of, 403-720
- Incheon St. Mary's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- ASA Physical Status 1 or 2
- Elective gynaecological laparoscopic surgery of ≥ 1h duration
Exclusion Criteria:
- Anti-emetics, steroids, or psychoactive medications within 24 h of study initiation
- Vomiting or retching in the 24 h preceding surgery
- Cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry
- Ongoing vomiting from gastrointestinal disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Palonosetron
|
0.075mg immediately before induction of anesthesia
|
|
Sham Comparator: Ramosetron
|
0.3mg immediately before induction of anesthesia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of postoperative nausea and vomiting for 48 hours after surgery
Time Frame: for 48 hours after surgery
|
for 48 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
severity of nausea for 48 hours after surgery
Time Frame: for 48 hours after surgery
|
for 48 hours after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
November 15, 2011
First Submitted That Met QC Criteria
November 17, 2011
First Posted (Estimate)
November 22, 2011
Study Record Updates
Last Update Posted (Estimate)
November 22, 2011
Last Update Submitted That Met QC Criteria
November 17, 2011
Last Verified
November 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Signs and Symptoms, Digestive
- Nausea
- Vomiting
- Postoperative Nausea and Vomiting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Serotonin Agents
- Serotonin Antagonists
- Serotonin 5-HT3 Receptor Antagonists
- Palonosetron
- Ramosetron
Other Study ID Numbers
- OC11MISI0027
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postoperative Nausea and Vomiting
-
Hafiz Muhammad HamzaFederal Government Polyclinic (Postgraduate Medical Institute)CompletedPostoperative Nausea and Vomiting (PONV)Pakistan
-
Cukurova UniversityTarsus UniversityCompletedNausea, Postoperative | Vomiting, Postoperative | APFEL RİSK SCORETurkey
-
GlaxoSmithKlineCompletedPostoperative Nausea and Vomiting | Nausea and Vomiting, PostoperativeUnited States, Spain, Philippines, Israel, Hong Kong, Thailand, United Kingdom, Hungary, Slovenia, Norway, Denmark
-
MonoSol RxCompletedNausea With Vomiting Chemotherapy-Induced | Nausea and Vomiting, PostoperativeIndia
-
Yeungnam University College of MedicineCompletedPostoperative Nausea | Postoperative VomitingKorea, Republic of
-
Oregon Health and Science UniversityCompletedPostoperative Vomiting and NauseaUnited States
-
Northwell HealthTerminatedPostoperative Pain | Postoperative Nausea | Postoperative VomitingUnited States
-
Hôpital Privé de Parly II - Le ChesnayCompletedPostoperative Nausea | Postoperative Vomiting | Postoperative EmesisFrance
-
Vestre VikenHF Kongsberg SykehusNorwegian Medical AssociationCompletedPostoperative Complications | Postoperative Pain | Postoperative Vomiting and Nausea | Mental Status Changes PostoperativeKazakhstan, Russian Federation
-
Acacia Pharma LtdPremier Research Group plc; Amicus CD LLCCompletedNausea and Vomiting, PostoperativeCanada, United States, Germany, France
Clinical Trials on palonosetron
-
Seoul National University Bundang HospitalRecruiting
-
Incheon St.Mary's HospitalUnknownPostoperative Nausea and VomitingKorea, Republic of
-
Xiamen LP Pharmaceutical Co., LtdCompletedNausea With Vomiting Chemotherapy-InducedUnited States
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Xiamen LP Pharmaceutical Co., LtdRecruitingChemotherapy-induced Nausea and VomitingUnited States
-
Consorzio OncotechCompletedNEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer (GIM15-NEPA)Chemotherapy-induced Nausea and Vomiting
-
Fujian Shengdi Pharmaceutical Co., Ltd.CompletedNausea and Vomiting Associated With Moderate Emetic Risk Anticancer AgentsChina
-
Helsinn Healthcare SACompletedPostoperative Nausea and VomitingRussian Federation, Ukraine
-
Zhuhai Beihai Biotech Co., LtdNot yet recruiting
-
University Hospital, BordeauxBordeaux Association for Training and Research in Obstetric Gynecology; Association...CompletedHyperfibrinolysis | Postpartum HemorrhageFrance